Myasthenia Gravis Research Highlights: AAN 2023

Myasthenia Gravis Research Highlights: AAN 2023 is organized by CheckRare, American Academy of CME, Inc..

Start date: July 15, 2023
End date: July 14, 2024

Description:
This 30-minute CME program highlights the latest clinical research about myasthenia gravis, a rare, autoimmune disease that targets the neuromuscular junction.

Treatment of myasthenia gravis is highly individualized and depends greatly on the myasthenia gravis subtype of each patient as well as each patient’s comorbidities. There are currently four drugs approved by the FDA, eculizumab, efgartigimod, ravulizumab, and rozanolixizumab. There are also treatments in development. Clinical trial data on these therapies were presented at the American Academy of Neurology Annual Meeting (AAN 2023) held in Boston, MA.

This CME program, hosted by Vera Bril, MD, of the University Hospital Network in Toronto, Canada, provides an overview of the latest clinical research presented at AAN 2023 focused on myasthenia gravis.

Learning Objectives:
After participating in the activity, learners should be better able to:

• Describe the latest research being presented to better manage people with myasthenia gravis and its clinical relevance